Recombinant GPIbα Receptor Composition for Precise vWF Binding Assays
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current diagnostic tests for von Willebrand Disease (vWD) are complex and imprecise, particularly the vWF:RCo assay, which suffers from interference and genetic variance, leading to underdiagnosis and inaccurate diagnosis of vWD types.
Innovation Solution
Development of recombinant polypeptides with specific mutations in the glycoprotein lbα extracellular domain, such as G233T, D235V, and K237V, that enhance binding affinity to von Willebrand Factor, allowing for more accurate vWD diagnosis.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Measurement precision
If the vWF:RCo assay is used to measure vWF activity, then binding information is obtained, but the assay suffers from interference from bilirubin, hemoglobin, HAMA, rheumatoid factor, and triglycerides, leading to imprecision
Solution Approach 1:
The patent uses a recombinant GPlbα polypeptide as an intermediary binding partner for vWF in diagnostic assays. This recombinant protein serves as a mediator that specifically binds vWF without being affected by the interfering substances (bilirubin, hemoglobin, HAMA, rheumatoid factor, and triglycerides) that plague traditional platelet-based assays. The recombinant GPlbα acts as a purified, controlled intermediary that eliminates the complexity and interference of whole platelet systems.
2Quantity of substance
If the vWF:Ag assay is used to measure total vWF concentration, then quantitative information is obtained, but the assay does not provide information about the quality of vWF present, failing to detect qualitative defects
Solution Approach 1:
The patent combines the quantitative capability of antigen detection with the functional binding information from GPlbα interaction. By using recombinant GPlbα polypeptide in binding assays, the method simultaneously assesses both the amount of vWF present and its functional binding quality. The merged approach provides comprehensive diagnostic information that encompasses both quantity and quality aspects of vWF.
3Adaptability or versatility
If multiple traditional tests are performed to diagnose different types of vWD, then diagnostic coverage is improved, but the diagnostic process becomes complex and time-consuming
Solution Approach 1:
The recombinant GPlbα polypeptide serves as a universal diagnostic tool that can detect and differentiate all types of vWD (Type 1, Type 2A, Type 2B, Type 2M, Type 2N, and Type 3) through a single binding assay platform. This multi-functional approach eliminates the need for multiple separate tests while maintaining the ability to diagnose diverse vWD conditions. The universal GPlbα binder provides a one-size-fits-all diagnostic solution that simplifies the workflow.
4Measurement precision
If the vWF:RCo assay is used to measure binding activity, then functional information is obtained, but genetic variance and polymorphisms at the Ristocetin binding site reduce assay accuracy
Solution Approach 1:
The patent extracts the essential GPlbα binding function from the complex platelet system and implements it using a recombinant polypeptide. By taking out only the critical extracellular domain of GPlbα that binds vWF, the invention creates a simplified, controlled assay system that is independent of genetic variations at the ristocetin binding site. The recombinant GPlbα polypeptide provides a consistent, genetically stable binding partner that eliminates the reliability issues associated with natural platelet variability.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The recombinant polypeptides provide higher binding affinity for von Willebrand Factor, enabling more precise vWD diagnosis and differentiation between vWD types, improving diagnostic accuracy and reducing underdiagnosis.
Implementation Method 1
recombinant polypeptides with specific mutations in the glycoprotein lbα extracellular domain, such as G233T, D235V, and K237V, that enhance binding affinity to von Willebrand Factor
Data Source
AI summary
Various aspects of the invention relate to recombinant polypeptides that specifically bind human von Willebrand Factor. Such recombinant polypeptides typically include a modified extracellular domain of platelet glycoprotein lbα that typically comprises at least one mutation selected from G233T, D235V, and K237V, and such recombinant polypeptides optionally include an oligomerization domain.